3:26-cv-09298
Knoa Pharma LLC v. Humanwell Pharma US Inc
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Knoa Pharma LLC (Connecticut) and Knoa Pharmaceuticals LLC (North Carolina)
- Defendant: Humanwell Pharmaceuticals US, Inc. (Missouri) and Epic Pharma, LLC (Delaware)
- Plaintiff's Counsel: FBT Gibbons LLP
- Case Identification: 3:26-cv-09298, D.N.J., 07/23/2026
- Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendants conduct business in the state, Epic Pharma has an active business registration in New Jersey, Defendants engaged in activities in New Jersey relevant to the ANDA submission, and Defendants have previously consented to venue in the district in a prior case.
- Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market generic versions of the opioid pain medication HYSINGLA® ER constitutes an act of infringement of four U.S. patents covering tamper-resistant, extended-release drug formulations.
- Technical Context: The technology relates to abuse-deterrent formulations for extended-release opioids, a field of significant public health and commercial importance due to the opioid abuse epidemic.
- Key Procedural History: This is a Hatch-Waxman action initiated in response to Defendants' Paragraph IV certification asserting that the patents-in-suit are invalid, unenforceable, or not infringed. The complaint notes the patents were transferred from Purdue Pharma to Plaintiffs on May 1, 2026. Defendants have previously consented to jurisdiction and venue in the District of New Jersey in a prior litigation.
Case Timeline
| Date | Event |
|---|---|
| 2006-08-25 | Priority Date for '416 and '809 Patents |
| 2010-12-22 | Priority Date for '740 Patent |
| 2012-06-28 | Application for '740 Patent becomes public |
| 2014-07-02 | Allowed claims for '740 Patent become public |
| 2014-07-14 | Issue fee paid for '740 Patent |
| 2014-08-19 | '740 Patent Issued |
| 2014-11-21 | '740 Patent listed in Orange Book |
| 2016-08-25 | Priority Date for '837 Patent; Application for '837 Patent becomes public |
| 2017-05-11 | Application for '416 and '809 Patents becomes public |
| 2017-08-07 | Allowed claims for '416 and '809 Patents become public |
| 2017-08-10 | Issue fee paid for '416 and '809 Patents |
| 2017-09-26 | '416 Patent Issued |
| 2017-09-27 | '416 Patent listed in Orange Book |
| 2017-10-03 | '809 Patent Issued |
| 2017-10-04 | '809 Patent listed in Orange Book |
| 2017-11-08 | Allowed claims for '837 Patent become public |
| 2017-11-20 | Issue fee paid for '837 Patent |
| 2018-01-23 | '837 Patent Issued; '837 Patent listed in Orange Book |
| 2026-05-01 | Asserted Patents transferred from Purdue to Knoa Pharma |
| 2026-06-09 | Defendants send Paragraph IV Certification Notice Letter |
| 2026-07-23 | Complaint Filed |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 8,808,740 - "Encased Tamper Resistant Controlled Release Dosage Forms"
The Invention Explained
- Problem Addressed: The patent's background section describes the problem of prescription drug abuse, particularly with opioid agonists, where abusers tamper with controlled-release formulations by crushing or using solvents to achieve an immediate and more potent dose for illicit use (e.g., parenteral or intranasal) '740 Patent, col. 1:21-31
- The Patented Solution: The invention is a multi-layered, solid dosage form, preferably with a core and an outer shell, designed to be physically robust and resistant to common tampering methods '740 Patent, col. 11:17-21 It uses matrix materials such as high molecular weight polyethylene oxide (PEO) to create a structure that is difficult to crush, while still providing a predictable, extended-release profile for the therapeutic agent '740 Patent, col. 2:37-52 The formulation is designed to maintain its controlled-release properties even if physically deformed (e.g., flattened) '740 Patent, col. 5:2-12
- Technical Importance: The technology provided a method to create an opioid formulation intended to deter common forms of abuse, a critical public health objective, while ensuring legitimate patients receive long-acting pain relief.
Key Claims at a Glance
- The complaint asserts independent claim 91 Compl. ¶42
- The essential elements of claim 91 are:
- A solid controlled release dosage form with a therapeutically effective amount of hydrocodone (or its salt) and a controlled release excipient.
- The amount of hydrocodone released is "proportional within 20% to elapsed time from 8 to 24 hours" under specified in-vitro dissolution conditions.
- The dosage form can be "flattened without breaking," with its thickness after flattening being no more than about 20% of its original thickness.
- The amount of hydrocodone released at 0.5 hours from the flattened form "deviates no more than about 20% points" from the release of a non-flattened form.
- The complaint alleges infringement of "one or more claims of the '740 Patent, including at least claim 91," reserving the right to assert other claims Compl. ¶43
U.S. Patent No. 9,872,837 - "Tamper Resistant Controlled Release Dosage Forms"
The Invention Explained
- Problem Addressed: As with the '740 Patent, the problem is the abuse of controlled-release opioid formulations via tampering methods designed to cause rapid drug release Compl. ¶28 Compl. ¶53
- The Patented Solution: The '837 Patent describes a solid, tamper-resistant dosage form of hydrocodone dispersed in a polyethylene oxide (PEO) matrix. A key feature of this solution is a manufacturing step where the dosage form is "cured at a temperature of at least 60° C. for at least 1 minute" Compl. ¶53 This curing process is intended to create a physically robust tablet that can be flattened without breaking and maintains its controlled-release properties even after physical deformation, thereby deterring abuse.
- Technical Importance: The invention focuses on a specific manufacturing process (curing) to achieve the desired physical resilience and abuse-deterrent properties in a PEO-based opioid tablet.
Key Claims at a Glance
- The complaint asserts independent claim 1 Compl. ¶53
- The essential elements of claim 1 are:
- A solid tamper resistant controlled release dosage form comprising hydrocodone (or its salt) dispersed in a PEO matrix with a specified average molecular weight.
- The dosage form is "cured at a temperature of at least 60° C. for at least 1 minute."
- A specific multi-point in-vitro dissolution profile for hydrocodone release at 2, 4, 8, 12, and 18 hours.
- The dosage form can be "flattened without breaking" to no more than about 20% of its original thickness.
- The amount of hydrocodone released at 0.5 hours from the flattened form "deviates no more than about 20% points" from a non-flattened form.
- The complaint alleges infringement of "one or more claims of the '837 Patent, including at least claim 1," reserving the right to assert other claims Compl. ¶54
U.S. Patent No. 9,770,416 - "Tamper Resistant Dosage Forms"
Technology Synopsis
The patent claims a pharmaceutical composition with an opioid in a high molecular weight PEO matrix. The invention centers on a specific manufacturing process where the dosage form is compression shaped and then "air cured by heated air, without compression," for a specified time and temperature, causing the dosage form to expand and harden to achieve its tamper-resistant properties Compl. ¶66
Asserted Claims
Independent claim 1 is asserted Compl. ¶66
Accused Features
The Humanwell ANDA Products are alleged to be compositions that meet the claim's requirements for the active agent, PEO characteristics, and the specific compression shaping and air curing manufacturing process Compl. ¶67
U.S. Patent No. 9,775,809 - "Tamper Resistant Dosage Forms"
Technology Synopsis
The patent claims a pharmaceutical composition with hydrocodone in a high molecular weight PEO matrix. Similar to the '416 patent, this invention focuses on a manufacturing method involving compression shaping followed by air curing "at a temperature above the softening temperature of the high molecular weight PEO" to create a hardened, tamper-resistant dosage form Compl. ¶79
Asserted Claims
Independent claim 1 is asserted Compl. ¶79
Accused Features
The Humanwell ANDA Products are alleged to be compositions that meet the claim's requirements regarding the active agent, PEO characteristics, and the specific manufacturing process involving compression shaping and curing above the PEO's softening temperature Compl. ¶80
III. The Accused Instrumentality
Product Identification
The accused instrumentalities are the "Humanwell ANDA Products," which are hydrocodone bitartrate extended-release tablets for which Defendants seek FDA approval under ANDA No. 215216 Compl. ¶1 Compl. ¶12 Compl. ¶38
Functionality and Market Context
The accused products are generic versions of Plaintiffs' HYSINGLA® ER drug, intended for the "management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate" Compl. ¶27 The complaint alleges the accused products will be available in 20 mg, 30 mg, 40 mg, and 60 mg tablet strengths Compl. ¶38 The lawsuit is an act of "artificial infringement" under the Hatch-Waxman Act, triggered by Defendants' submission of the ANDA seeking to market a generic equivalent prior to the expiration of the Asserted Patents Compl. ¶1
IV. Analysis of Infringement Allegations
No probative visual evidence provided in complaint.
U.S. Patent No. 8,808,740 Infringement Allegations
| Claim Element (from Independent Claim 91) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A solid controlled release dosage form comprising: a therapeutically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a controlled release excipient; | The complaint alleges on information and belief that the Humanwell ANDA Products are a solid controlled release dosage form containing hydrocodone and a controlled release excipient. | ¶43 | col. 4:45-48 |
| wherein the amount of hydrocodone or salt thereof released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution... | The complaint alleges on information and belief that the accused products meet this specific dissolution profile. | ¶43 | col. 2:45-52 |
| and the dosage form can be flattened without breaking, wherein the thickness of the dosage form after flattening corresponds to no more than about 20% of the thickness of the dosage form before flattening; | The complaint alleges on information and belief that the accused products can be flattened without breaking and meet this thickness requirement. | ¶43 | col. 5:2-6 |
| and the amount of hydrocodone or salt thereof released at 0.5 hour from a flattened dosage form deviates no more than about 20% points from a non-flattened dosage form as measured by an in-vitro dissolution... | The complaint alleges on information and belief that the accused products' release profile after flattening meets this deviation requirement compared to a non-flattened form. | ¶43 | col. 5:6-12 |
Analysis of U.S. Patent No. 9,872,837
The complaint asserts infringement of U.S. Patent No. 9,872,837, but the patent document itself was not provided as an exhibit. The infringement allegations in the complaint are conclusory and mirror the language of claim 1 Compl. ¶53 Compl. ¶54 Without the patent specification, it is not possible to construct a complete claim chart with the required patent citations for the teachings of the claim limitations. The core infringement theory alleges that the Humanwell ANDA Products are solid, tamper-resistant, controlled-release dosage forms of hydrocodone in a PEO matrix that are manufactured using a curing step and exhibit the specific dissolution and physical flattening properties recited in claim 1 Compl. ¶54
Identified Points of Contention
- Factual/Quantitative Questions: The primary points of contention will be factual and quantitative. The complaint makes its allegations "on information and belief" without presenting any test data. The dispute will likely revolve around competing laboratory tests and expert testimony to determine if the Humanwell ANDA Products actually meet the specific numerical thresholds required by the claims for dissolution rates (e.g., "proportional within 20%"), physical properties (e.g., "flattened to no more than about 20%"), and manufacturing parameters (e.g., "cured at a temperature of at least 60° C.").
- Scope Questions: A potential legal dispute may arise over the interpretation of claim terms that define the boundaries of the invention. For example, the meaning of "flattened without breaking" or what it means for a release profile to be "proportional" will be critical for determining infringement.
V. Key Claim Terms for Construction
The Term: "proportional within 20% to elapsed time" (from '740 Patent, claim 91)
Context and Importance
This term defines the controlled-release characteristic of the invention. The method of calculating "proportionality" and the acceptable range of deviation ("within 20%") will be a central battleground in the infringement analysis. Practitioners may focus on this term because its construction will determine whether the accused product's measured release profile falls inside or outside the claimed scope.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The specification states that its provided mathematical formula for proportionality is "not intended to be limiting," which could support an argument that other accepted methods of determining linear release kinetics may apply '740 Patent, col. 7:4-21
- Evidence for a Narrower Interpretation: The specification provides a specific, multi-part mathematical formula for calculating proportionality based on release amounts at four different time points '740 Patent, col. 7:4-21 A party could argue that this explicit definition provides the sole and exclusive method for assessing this claim limitation.
The Term: "flattened without breaking" (from '740 Patent, claim 91)
Context and Importance
This term is crucial as it defines a key physical attribute of the tamper-resistance. Whether the accused product "breaks" when flattened will be a dispositive factual question, and the legal definition of "breaking" will be paramount.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The specification suggests that "breaking" means catastrophic failure into separate pieces, stating that after flattening, "edge splits and cracks may occur" '740 Patent, col. 26:48-50 This implies that the mere presence of cracks does not constitute "breaking."
- Evidence for a Narrower Interpretation: The patent's stated object is to provide a dosage form that is "resistant to crushing" to prevent abuse '740 Patent, col. 2:3-5 A party could argue that any crack or fracture that compromises the controlled-release matrix sufficiently to allow for easier extraction of the active agent should be considered "breaking" in the context of the patent's purpose.
VI. Other Allegations
- Indirect Infringement: The complaint alleges that upon FDA approval, Defendants' commercial manufacture, use, sale, and importation of the Humanwell ANDA Products "with its proposed labeling" will infringe the asserted patents Compl. ¶51 This allegation, focusing on the instructions provided with the product, forms the basis for a claim of induced infringement.
- Willful Infringement: The complaint seeks a finding of willful infringement Compl. ¶91(f) The basis for this allegation is pre-suit knowledge of the patents. The complaint alleges Defendants knew of the patents because they are listed in the FDA's Orange Book for HYSINGLA® ER and because the patent applications were publicly available prior to Defendants' ANDA filing Compl. ¶44 Compl. ¶45 Compl. ¶57 Compl. ¶58 Compl. ¶70 Compl. ¶71 Compl. ¶83 Compl. ¶84
VII. Analyst's Conclusion: Key Questions for the Case
- A central question in this case will be one of empirical fact: will discovery and expert testing show that the Defendants' generic product possesses the specific, quantitative physical and chemical properties recited in the claims? The dispute will likely feature a "battle of the experts" over laboratory data concerning dissolution profiles and the physical behavior of the tablets under stress.
- A second core issue will be one of claim construction: how will the court define key performance-based limitations such as "proportional within 20% to elapsed time" and "flattened without breaking"? The outcome of the case may hinge on whether these terms are given a narrow, formulaic interpretation or a broader, more functional one.
- For the patents focused on manufacturing ('837, '416, and '809), a key evidentiary question will be whether the Defendants' manufacturing process for their generic product includes the specific "curing" steps-defined by temperature, time, and method (e.g., heated air without compression)-recited in the asserted claims.